SCHEMBL10068612

SCHEMBL10068612

COc1cc2oc(-c3ccc(O)c(O)c3)cc(=O)c2cc1OC

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 8/20 0.69
CSNK2B P67870 8/20 0.69
CSNK2A1 P68400 8/20 0.69
KDM4E B2RXH2 3/20 0.67
CYP2C19 P33261 3/20 0.67
ALDH1A1 P00352 2/20 0.67
HSD17B10 Q99714 2/20 0.67
CYP3A4 P08684 2/20 0.67
CYP2C9 P11712 2/20 0.67
HPGD P15428 2/20 0.67
ESR2 Q92731 1/20 0.65
TERT O14746 1/20 0.65
POLH Q9Y253 1/20 0.65
CYP2D6 P10635 2/20 0.64
TP53 P04637 1/20 0.64
FYN P06241 1/20 0.63
MEN1 O00255 1/20 0.63
POLB P06746 1/20 0.63
MAPT P10636 1/20 0.63
MAPK1 P28482 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8934505 0.92 CYP1A1 (0.69) CSNK2A2CSNK2BCSNK2A1KDM4ECYP2C19
SCHEMBL8934614 0.86 KDM4E (0.74) CSNK2A2CSNK2BCSNK2A1KDM4ECYP2C19
SCHEMBL7603180 0.85 FYN (0.73) CSNK2A2CSNK2BCSNK2A1KDM4ECYP2C19
SCHEMBL2218499 0.84 POLH (0.75) CSNK2A2CSNK2BCSNK2A1KDM4ECYP2C19
SCHEMBL4160578 0.84 CSNK2A2 (0.81) CSNK2A2CSNK2BCSNK2A1KDM4ECYP2C19
SCHEMBL10037938 0.82 CSNK2A2 (0.74) CSNK2A2CSNK2BCSNK2A1KDM4ECYP2C19
SCHEMBL31552889 0.82 ALDH1A1 (0.76) CSNK2A2CSNK2BCSNK2A1KDM4ECYP2C19
SCHEMBL7127301 0.82 CYP1A1 (0.86)
SCHEMBL14697033 0.82 CSNK2A2 (1.00) CSNK2A2CSNK2BCSNK2A1KDM4ECYP2C19
SCHEMBL6796626 0.82 TERT (0.77) CSNK2A2CSNK2BCSNK2A1TERT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8466195-B2 Methods and compositions for treating complications of diabetes and vascular diseases using flavones SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2013-06-18 US disclosed
US-20120016016-A1 METHODS AND COMPOSITIONS FOR TREATING COMPLICATIONS OF DIABETES AND VASCULAR DISEASES USING FLAVONES THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2012-01-19 US disclosed
WO-2010105253-A2 METHODS AND COMPOSITIONS FOR TREATING COMPLICATIONS OF DIABETES AND VASCULAR DISEASES USING FLAVONES THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016016-A1 METHODS AND COMPOSITIONS FOR TREATING COMPLICATIONS OF DIABETES AND VASCULAR DISEASES USING FLAVONES SLC5A2, LIPG, TIE1 CSNK2A2 4451/4885CSNK2B 4604/4885CSNK2A1 4464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.